Cyclin-Dependent Kinase 4
"Cyclin-Dependent Kinase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 4 is a key regulator of G1 PHASE of the CELL CYCLE. It partners with CYCLIN D to phosphorylate RETINOBLASTOMA PROTEIN. CDK4 activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P16.
Descriptor ID |
D051358
|
MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.875 D12.644.360.250.451 D12.776.167.200.451 D12.776.476.250.451
|
Concept/Terms |
Cyclin-Dependent Kinase 4- Cyclin-Dependent Kinase 4
- Cyclin Dependent Kinase 4
- Cdk4 Cyclin-Dependent Kinase
- Cdk4 Cyclin Dependent Kinase
- Cyclin-Dependent Kinase, Cdk4
- Cdk4 Protein
- Cdk4 Protein Kinase
- Protein Kinase, Cdk4
- p34PSK-J3 Kinase
- p34PSK J3 Kinase
- Cell Division Protein Kinase 4
- PSK-J3 Kinase
- PSK J3 Kinase
- Cyclin D-Dependent Kinase CDK4
- Cyclin D Dependent Kinase CDK4
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 4".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 4" by people in this website by year, and whether "Cyclin-Dependent Kinase 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 0 | 3 | 3 |
1996 | 0 | 1 | 1 |
1997 | 0 | 3 | 3 |
1998 | 0 | 5 | 5 |
1999 | 0 | 3 | 3 |
2000 | 0 | 2 | 2 |
2001 | 0 | 3 | 3 |
2003 | 0 | 5 | 5 |
2004 | 0 | 5 | 5 |
2005 | 1 | 2 | 3 |
2006 | 2 | 3 | 5 |
2007 | 0 | 2 | 2 |
2008 | 1 | 0 | 1 |
2009 | 0 | 2 | 2 |
2010 | 0 | 2 | 2 |
2011 | 0 | 3 | 3 |
2012 | 1 | 1 | 2 |
2013 | 2 | 3 | 5 |
2014 | 2 | 0 | 2 |
2015 | 1 | 1 | 2 |
2016 | 1 | 1 | 2 |
2017 | 5 | 3 | 8 |
2018 | 4 | 3 | 7 |
2019 | 2 | 4 | 6 |
2020 | 2 | 2 | 4 |
2021 | 4 | 7 | 11 |
2022 | 0 | 2 | 2 |
2023 | 0 | 9 | 9 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 4" by people in Profiles.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treat Rev. 2024 Jan; 122:102668.
-
Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All. Cancer Res. 2023 10 02; 83(19):3165-3167.
-
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res. 2023 10 02; 83(19):3264-3283.
-
Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma. Blood Adv. 2023 07 25; 7(14):3361-3365.
-
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955.
-
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA. Pharmacoeconomics. 2023 06; 41(6):709-718.
-
CDK4/6 inhibitor palbociclib promotes SARS-CoV-2?cell entry by down-regulating SKP2 dependent ACE2 degradation. Antiviral Res. 2023 04; 212:105558.
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
-
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.